OL

Oriella Ltd.

Description

Oriella Ltd. is a prominent private equity and technology investor.

Investor Profile

Oriella Ltd. has backed more than 3 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 0 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series Unknown, Series B rounds (top funding stages).
  • Majority of deals are located in Israel.
  • Strong thematic focus on Biotechnology, Medical, Pharmaceutical.

Stage Focus

  • Series Unknown (67%)
  • Series B (33%)

Country Focus

  • Israel (100%)

Industry Focus

  • Biotechnology
  • Medical
  • Pharmaceutical
  • Food And Beverage
  • Manufacturing
  • Waste Management
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Oriella Ltd. frequently co-invest with?

Shavit Capital
Asia, Yerushalayim, Israel, Jerusalem
Co-Investments: 1
Peregrine Ventures
Asia, Tel Aviv, Israel, Or Yehuda
Co-Investments: 1
CF
North America, Louisiana, United States, Shreveport
Co-Investments: 1
Dafna Capital Management
North America, California, United States, Los Angeles
Co-Investments: 1
Mirae Asset Venture Investment
Asia, Kyonggi-do, South Korea, Seongnam
Co-Investments: 2
aMoon Fund
Asia, HaMerkaz, Israel, Ra'anana
Co-Investments: 1
Biotechnology Value Fund
North America, California, United States, San Francisco
Co-Investments: 1
HBL Hadasit Bio Holdings
Asia, Yerushalayim, Israel, Jerusalem
Co-Investments: 2
Flerie Invest
Europe, Stockholms Lan, Sweden, Stockholm
Co-Investments: 2
Pavilion Capital
North America, New York, United States, New York
Co-Investments: 2

Which angels does Oriella Ltd. often collaborate with?

Tal Shapira
Asia, Israel
Shared Deals: 1
Eddy Shalev
Asia, Israel
Shared Deals: 1

What are some of recent deals done by Oriella Ltd.?

Omnix Medical

Jerusalem, Yerushalayim, Israel

Omnix Medical develope and commercialize highly effective antibiotic agents against resistant pathogenic bacterial strains.

BiotechnologyHealth CarePharmaceutical
Series COct 15, 2025
Amount Raised: $25,000,000
TripleW Ltd.

Netanya, HaMerkaz, Israel

TripleW upcycles food waste into high-demand, high-value lactic acid, the building block of PLA bioplastics.

BiotechnologyFood and BeverageManufacturingWaste Management
Series BMar 1, 2023
Amount Raised: $16,500,000
KAHR medical

Jerusalem, Yerushalayim, Israel

KAHR Medical develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases.

BiotechnologyMedicalPharmaceutical
Series UnknownJun 16, 2021
Amount Raised: $46,500,000
KAHR medical

Jerusalem, Yerushalayim, Israel

KAHR Medical develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases.

BiotechnologyMedicalPharmaceutical
Series UnknownFeb 25, 2020
Amount Raised: $18,000,000